DuoResp Spiromax (budesonide/formoterol) / Teva - LARVOL DELTA

EXACT@home: Expertise Asthma COPD Program with Digital Support (clinicaltrials.gov) - P3 | N=138 | Recruiting | Sponsor: Franciscus Gasthuis | Trial completion date: Jun 2025 ➔ Apr 2026

Trial completion date • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

The match between adhesive mixture powder formulations for inhalation and the inhaler device. (PubMed, Eur J Pharm Sci) - "To address this question, three budesonide-containing reservoir DPIs: Novopulmon Novolizer®, Giona Easyhaler® and DuoResp Spiromax®, were analyzed using the Next Generation Impactor, NGI...Tested in the Easyhaler device, the prototype formulations produced low fine particle fractions, but interestingly, the formulation with the smallest carrier particle size yielded the highest FPF. It can be concluded that there is a link between inhaler design and the effect of carrier particle size, where larger carriers provide better dispersion in cyclone-type devices while smaller carriers seem to be more beneficial for inhalers which has a straight flow path for the powder formulation."

Journal

EXACT@home: Expertise Asthma COPD Program With Digital Support (clinicaltrials.gov) - P3 | N=138 | Recruiting | Sponsor: Franciscus Gasthuis

New P3 trial • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

ELIOT: Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma (clinicaltrials.gov) - P3 | N=485 | Completed | Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Phase classification: P4 ➔ P3

Phase classification • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

"Switches LAMA/LABA/ICS➡️Trimbow LAMA/LABA➡️Duaklir Genuair/Spiolto Respimat/Bevespi Aerosphere LABA/ICS➡️Fostair/Symbicort/DuoResp Spiromax etc LAMA➡️Spiriva/Braltus etc @GSK please find Ellipta alternative so we can use your once daily drugs @Novartis pls replace Breezhaler 3/" (@DrHugoA)

Inhaled long-acting bronchodilators with or without inhaled glucocorticosteroids for preventing hospitalizations and death in elderly patients with chronic obstructive pulmonary disease. Broncodilatatori inalatori a lunga durata d’ azione con o senza glucocorticosteroidi inalatori nella prevenzione della re-ospedalizzazione e/o della mortalità in pazienti anziani affetti da malattia cronica... (clinicaltrialsregister.eu) - P4; N=1032; Ongoing; Sponsor: AZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA

Clinical • New P4 trial • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Respiratory Diseases

Assessment of inhalation errors, training time and patient preference for DuoResp® Spiromax® and Symbicort® Turbuhaler® in patients with asthma and COPD. (PubMed, Eur Clin Respir J) - "Overall, 79.5% of patients stated that they preferred DuoResp® Spiromax® as their first option over Symbicort® Turbuhaler®. The findings of this study may be useful in developing effective inhaler training programmes and thus improve outcomes in asthma and COPD."

Clinical • Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases